Skip to main content

An independent expert advisory committee recommended 21-0 that the FDA grant emergency use authorization for a fourth COVID-19 vaccine, made by Novavax. Cindy Gay, MD, MPH, discusses the Novavax data, its effectiveness, and how it’s different from the other three COVID-19 vaccines.


An independent expert advisory committee recommended 21-0 that the FDA grant emergency use authorization for a fourth COVID-19 vaccine, made by Novavax. We sit down with Cindy Gay, MD, MPH, Associate Professor of Medicine in the Division of Infectious Diseases at the UNC School of Medicine to discuss the Novavax data, its effectiveness, and how it’s different from the other three COVID-19 vaccines.

For more information regarding COVID-19 vaccines, head to https://www.unchealthcare.org/coronavirus/vaccines/